Publication: Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer
Loading...
Date
2009
Authors
Zardawi, Sarah J. ; O’Toole, Sandra A. ; Sutherland, Robert L. ; Musgrove, Elizabeth A.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
There has been a significant decrease in
mortality from breast cancer in the last two decades.
This has been attributed to the introduction of
mammographic screening and to the development of
specialised therapies, notably anti-estrogens such as
tamoxifen in estrogen receptor (ER) positive tumours,
and adjuvant chemotherapy. More recently monoclonal
antibodies such as trastuzumab directed against Her2-
overexpressing tumours show significant promise in
improving outcome from this aggressive subtype. While
there have been significant advances, a number of
clinical challenges still remain, particularly development
of targeted therapies for other forms of breast cancer
lacking ER or Her2, such as the aggressive basal-like
carcinomas. Identification of new therapeutic targets in
poor prognosis groups will be critical to further
improvements in breast cancer treatment. Proper
functioning of the Hedgehog, Notch and Wnt signalling
pathways is required for normal development during
early life and these pathways also play a key role in
regulation and maintenance of stem cells. Increasing
evidence implicates dysregulation of these pathways in the development and progression of a number of
malignancies, including breast cancer. This review
presents the current evidence for aberrations in these
pathways in breast cancer and proposes that the
Hedgehog, Notch and Wnt signalling pathways may
represent novel therapeutic targets.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.